In single-entity oral tablet manufacture, pyridoxine hydrochloride is formulated as a water-soluble active ingredient in an immediate-release hydrophilic matrix at unit doses of 10 mg, 25 mg, 50 mg, or 100 mg. At a compressed core mass of 150–400 mg, the active concentration ranges from 5% w/w to 25% w/w; a 50 mg strength tablet with a 250 mg core corresponds to 20% w/w. Pyridoxine hydrochloride readily dissolves in purified water during wet granulation, and the resulting solution can act as a non-polymeric binder after drying. The manufacturing sequence therefore follows a deliberate cycle of high-shear granulation, wet sizing, fluid-bed drying, dry sizing, lubrication, and rotary compression. The dry powder mixture is charged into a high-shear granulator and wetted with purified water or pregelatinized starch suspension until the impeller torque reaches a pre-validated end point; the wet mass is then passed through a 2.0–4.0 mm screen and dried to a loss-on-drying range of 1.5–2.5%. The dried granulate is milled through a 0.8–1.0 mm screen, blended with a disintegrant such as croscarmellose sodium at 2.0–4.0% w/w, and lubricated with magnesium stearate at 0.5–1.0% w/w. Compression is performed on a rotary tablet press at 10–25 kN compression force, producing tablet breaking force of 80–150 N when measured by USP <1217>; friability remains not more than 1.0% under USP <1216>. Field observations on high-speed presses indicate that granule LOD below 1.5% correlates with capping and lamination above 80 rpm press speed, whereas LOD above 2.5% increases picking and sticking on tooling. Release testing includes USP <905> for content uniformity and, where the product monograph specifies dissolution, USP <711> Apparatus 2 at 50 rpm in 900 mL water with not less than 80% (Q) dissolved in 30 min is the commonly applied acceptance criterion.

Compliance with ICH Q3D elemental impurity limits and ICH Q3C residual solvent limits is maintained through vendor qualification and control of the API synthesis route, while batch release and stability follow 21 CFR 210 and 21 CFR 211. Because pyridoxine hydrochloride is sensitive to alkaline conditions, it is not combined with sodium bicarbonate or other alkalizing excipients in a conventional immediate-release core; prolonged wet mass contact at pH above 6.0 may accelerate degradation and should be avoided. Photostability is evaluated according to ICH Q1B; coated tablets may require opaque HDPE containers or aluminium blister packaging if confirmatory studies demonstrate light-induced discoloration. The terminal dosage form remains an uncoated or film-coated immediate-release tablet intended for oral administration, with the film coat selected only from systems whose plasticizer and pigment load do not retard dissolution below the registered specification.

What Changes After Roller Compaction of Pyridoxine HCl for Hard-Shell Capsule Filling?

Roller compaction changes the handling behaviour of pyridoxine hydrochloride in hard-shell capsule filling from a poorly flowing crystal mass to a densified granulate with reduced segregation risk. Unit doses are typically 10 mg to 50 mg per capsule, with a total fill weight of 180–320 mg depending on capsule size, placing the active loading between 5% w/w and 15% w/w. The API is first milled or sieved through a 0.5 mm screen and blended with microcrystalline cellulose, lactose monohydrate, or dibasic calcium phosphate dihydrate in a diffusion mixer. The blend is compacted on a roller compactor equipped with knurled or ribbed rolls at roll force of 4–10 kN/cm, roll speed 2–8 rpm, and gap 2–4 mm; the resulting ribbons are milled through a 1.0 mm screen and then blended with crospovidone and sodium stearyl fumarate before encapsulation. Because published ribbon density targets specific to pyridoxine HCl are limited, the roller compaction parameters are established through design-of-experiments using envelope density and USP <616> bulk and tapped density as response variables. The finished blend is filled on a tamping-pin or dosing-disc capsule machine to fill weight variation not exceeding ±5%, with periodic in-process checks of net fill weight and closure integrity.

Release testing follows USP <905> or Ph. Eur. 2.9.40 for uniformity of dosage units; dissolution is conducted according to USP <711> or Ph. Eur. 2.9.3, with water or 0.1 N hydrochloric acid as media for immediate-release capsules. Because pyridoxine hydrochloride is highly water-soluble, dissolution failure is more frequently associated with capsule shell cross-linking, fill-weight underdosing, or hydrophobic lubrication than with the API itself. The gelatin or HPMC capsule shell should be qualified for low-moisture storage, and desiccant or aluminium blister packaging is used when stability data show moisture uptake above the shell specification. The terminal dosage form is a hard-shell capsule intended for oral administration, supplied as a single-entity or combination product.

Direct blending of 5–50 mg pyridoxine hydrochloride into a 1.0–3.0 g single-dose powder sachet creates a low-dose homogeneity problem that is solved by geometric pre-dilution rather than granulation. In this oral powder for solution format, the active concentration is 0.2–2.0% w/w because the bulk of the sachet is a water-soluble carrier such as dextrose, sucrose, sorbitol, or mannitol, plus flavour and sweetener. The API and carrier are separately passed through a 0.5–1.0 mm sieve, then combined in stepwise portions to form a master pre-blend before final mixing in a double-cone or bin blender. The final blend is filled on vertical form-fill-seal equipment using a polyethylene/aluminium/polyester laminate; seal integrity and fill weight are monitored in process. Release testing includes USP <905> or Ph. Eur. 2.9.40 for uniformity of dosage units, moisture content not more than 2.0%, and reconstitution time after the dose is dispersed in water. The terminal dosage form is an oral powder for solution, administered after complete dissolution in potable water; it is not used for parenteral administration.

Sterile Injectable Formulation Windows and Terminal Sterilization Limits

Pyridoxine hydrochloride injection is an aqueous solution formulated at 100 mg/mL (equivalent to 10% w/v) and, in some regional products, at 50 mg/mL. The solution is compounded in a 316L stainless steel vessel under a nitrogen blanket to limit oxidative discoloration; Water for Injection is charged first and cooled or maintained at 20–25°C before the API is added under continuous agitation. The pH is measured and, when necessary, adjusted with dilute hydrochloric acid or sodium hydroxide to the compendial range of 2.0–3.8. The bulk solution is filtered through a 0.22 µm sterilizing-grade PVDF or PES filter into Type I borosilicate glass vials or ampoules. Terminal steam sterilization at 121.1°C is applied with an accumulated F0 of not less than 8.0 and typically not more than 15.0; excessive thermal input beyond the registered cycle can intensify yellow coloration and should be prevented by controlled load configuration and steam penetration studies. Filter integrity testing, sterilization cycle validation, and filter wetted integrity are performed under 21 CFR 211.167, and the line is requalified after filter or filling system changes.

Release and stability specifications include USP <1> parenteral requirements, USP <71> sterility, USP <788> particulate matter, USP <790> visible particulates, and USP <85> bacterial endotoxins; the endotoxin limit is calculated from the maximum bolus dose stated in the labelling and the route of administration. Elemental impurities are controlled by ICH Q3D, and extractables/leachables from the rubber stopper and glass container closure are assessed under ICH-mapped stability protocols. Because pyridoxine hydrochloride injection is light sensitive, the filled vials or ampoules are packed in light-protective cartons or aluminium overpouch, and light exposure during inspection and packaging is minimised. The terminal dosage form is a sterile intravenous or intramuscular injection supplied in single-dose or multi-dose containers, with headspace flushing using nitrogen to reduce oxidative degradation.

B-Complex Multi-API Granulation with Sprayed Polyvinylpyrrolidone Binder

Fluid-bed spray granulation for B-complex tablets containing pyridoxine hydrochloride places the API in a low-dose regime of 1–10 mg per tablet, with a core mass of 300–600 mg; the active ratio is therefore 0.5–5.0% w/w, and the dominant manufacturing risk is content uniformity rather than dissolution or compressibility. The granulation charge includes thiamine hydrochloride or thiamine mononitrate, riboflavin, nicotinamide, calcium pantothenate, folic acid, and cyanocobalamin, with pyridoxine hydrochloride pre-blended in a water-soluble carrier or dissolved in the aqueous polyvinylpyrrolidone K30 binder solution at 2–5% w/w of dry charge. Riboflavin and cyanocobalamin are pre-milled or triturated because their low dose and cohesive particle behaviour create local concentration fluctuation if charged directly through the high-shear mixer port. The spray granulation is performed on a top-spray fluid-bed system with inlet air temperature 50–70°C, product temperature 30–40°C, and spray rate controlled to maintain a stable dew point differential; production-scale runs show that spray rate must be reduced when inlet air dew point exceeds 10°C to avoid uncontrolled agglomerate growth and filter bag blinding. Drying continues to LOD 1.5–3.0%, followed by milling through a 0.8 mm screen, blending with disintegrant and magnesium stearate, and rotary compression. The terminal dosage form is a film-coated B-complex tablet; the coating system is selected for light protection, and its aqueous coating process is validated to avoid moisture ingress into the core. Release tests include USP <905> or Ph. Eur. 2.9.40 for uniformity, USP <711> or Ph. Eur. 2.9.3 for dissolution, and ICH Q3D elemental impurity control for the multi-source vitamin premix.

When Effervescent Granules Require Moisture Exclusion Beyond Standard Tablet Coatings

In effervescent oral dosage forms, pyridoxine hydrochloride is embedded in a dry acid-base reaction system containing citric acid, tartaric acid, and sodium bicarbonate or sodium carbonate. The active dose is typically 25–100 mg per tablet, while the total tablet mass is 3.0–5.0 g, giving an active concentration of 0.5–2.0% w/w; sachet-based effervescent granules generally have fill weights of 1.0–3.0 g and similar proportions. The manufacturing process is dry by necessity: wet granulation would initiate premature carbon dioxide release and produce a sticky, non-compressible mass. Direct compression or roller compaction is therefore used, with blending and compression performed in rooms controlled to 20–25°C and not more than 25% RH. The granulate is transferred in sealed stainless-steel containers to the rotary tablet press, where hardened tooling and compression force selected to achieve tablet breaking force of 60–120 N prevent capping without creating an over-hydrated surface. Disintegration is tested in 200 mL of water at 20°C; effervescent tablets and granules must disperse within 5 min according to Ph. Eur. 2.9.1, after which pyridoxine hydrochloride dissolves rapidly. The terminal dosage form is an effervescent tablet or effervescent granules for oral solution, intended for dispersion in water before oral administration.

Packaging for effervescent pyridoxine products differs from ordinary coated tablets because the reactive acid and carbonate system has a water-vapour threshold below which standard PVC blister films are inadequate. Aluminium/aluminium blister sheets or HDPE containers with desiccant can maintain internal headspace humidity below the critical point; the choice is confirmed by moisture permeability testing and long-term stability under ICH climatic zones. Fabrication of the effervescent granulate should avoid contact with uncoated steel surfaces for extended periods because residual moisture and acidic dust can induce surface corrosion, which introduces metallic contaminants that require control under ICH Q3D. The production layout segregates citric acid and sodium bicarbonate pre-blends until the final dry granulation step, preventing uncontrolled reaction with ambient moisture. Dissolution or disintegration acceptance is supplemented by content uniformity testing per USP <905> or Ph. Eur. 2.9.40, and the final sachet or blister line includes checkweighing and seal integrity testing as critical in-process controls.